Associated Genetic Biomarkers
BST2 status serves as an inclusion eligibility criteria in 2 clinical trials, of which 0 are open and 2 are closed. Of the trials that contain BST2 status as an inclusion criterion, 2 are phase 1/phase 2 (0 open).
The most frequent alteration to serve as an inclusion eligibility criterion is BST2 Expression .
Significance of BST2 in Diseases
Malignant Solid Tumor +
BST2 is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 0 are open and 2 are closed. Of the trials that contain BST2 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.